Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.

Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.

Abstract: The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84° C., preferably 80° C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 log10 in comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Abstract: This invention provides novel compositions to inhibit the aggregation of amyloid proteins. In various embodiments the compositions comprise a molecular tweezers that binds lysine and/or arginine and thereby inhibits the aggregation of amyloidogenic proteins.

Abstract: The present application relates to an affinity material useful in antibody purification.

Abstract: The invention relates to a method for reducing the viral and microbial content of biological extracts which contain solids. It is provided that the method comprises the steps (a) provision of the biological extract which contains solids, comprising a biologically active substance, selected from enzymes, proteins and peptides, or a mixture of such substances; and (b) subjecting the biological extract provided in step (a) to a high-pressure treatment; wherein the biological activity of the biological extract which contains solids after the high-pressure treatment is at least 50% of the biological activity of the biological extract which contains solids before the high-pressure treatment.

Abstract: A substrate for inkjet printing, which includes a photoresist layer structure on a base substrate, and a method of manufacturing the same are provided. The substrate, which has high surface tension variation and slight thickness variation, may be manufactured at a low cost. The substrate includes a discontinuous organic layer structure made of a fluorinated hydrocarbon or a polysiloxane on the photoresist layer structure.

Abstract: A flat panel display and a method of manufacturing the same, which allows the formation of an organic film by inkjet printing while avoiding overflow of ink into adjacent areas, thus increasing the uniformity of thickness of the organic film and decreasing manufacturing costs. The flat panel display includes a substrate, a first electrode layer formed on the substrate, ink with material for a light emission layer formed on an active area of the first electrode layer, a repellant area formed of organic material located around the active area, and a border area also formed of organic material located between the active area and the repellant area. A surface energy of the border area is higher than a surface energy of the repellant area.

Abstract: The invention relates to a method for reducing the virus and micro-organism content of biological extracts which contain solids. It is provided that the method comprises the steps (a) provision of a biological extract which contains solids in the form of a suspension, which consists of a liquid phase and solid particles dispersed therein, wherein the extract in step (a) comprises a mixture of enzymes, proteins and peptides, some of which is dissolved in the liquid phase and some of which can be bound to the solid particles or is present in pulverulent, solid form; and (b) irradiation of the biological extract provided in step (a); wherein the radiation used for the irradiation is selected from the group comprising ultra-violet radiation, x-ray radiation, ? radiation and ? radiation; and the enzymic activity of the biological extract which contains solids after irradiation is at least 50% of the enzymic activity of the biological extract which contains solids before irradiation.

Abstract: The invention relates to a method for producing pancreatin with reduced viral and microbial contamination, comprising the steps of (a) providing the pancreatin in solid form with a residual moisture of 0.5 weight % or less, down to almost zero, based on the pancreatin provided; (b) subjecting the pancreatin provided in step (a) to a heat treatment at a temperature of 84° C., preferably 80° C. and below; wherein, the biological activity of the pancreatin obtained in step (b) corresponds to at least 50% of the biological activity of the pancreatin provided in step (a); and the viral infectiousness of the pancreatin obtained in step (b) has been reduced by a factor of more than 1 log10 in comparison with the viral infectiousness of the pancreatin provided in step (a), as well as a pancreatin produced according to this method and its use for producing a medicine or a nutritional supplement.

Abstract: An organic light-emitting diode (OLED) with an increased service life and a method of manufacturing the same are provided. The OLED is subjected to electromagnetic radiation with a spectrum that at least partially overlaps the absorption spectrum of an organic material layer of the OLED. As a result, the OLED has a longer service life, reduced decay in its initial brightness, and more saturated color than a conventional OLED.

Abstract: An organic light emitting device (OLED) comprising an anode, an organic emissive layer, a cathode, and an ion-complexing material layer, and a display using the OLED, are provided. The ion-complexing material layer is arranged between the anode and the cathode.

Abstract: The invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates and stereoisomers thereof, wherein A, B, E, G, W, X, Y, Z, o, and R1 are as disclosed herein (“Compound(s) of the Invention”), which are useful as cardio-protective and/or neuro-protective agents. The invention also provides pharmaceutical compositions comprising a Compound of the Invention and methods for treating, preventing and/or managing a vascular, cardiovascular or neurological disease or disorder, comprising administering to a patient in need thereof a Compound of the Invention.

Abstract: The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like.

Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

Abstract: A flat panel display and a method of manufacturing the same, which allows the formation of an organic film by inkjet printing while avoiding overflow of ink into adjacent areas, thus increasing the uniformity of thickness of the organic film and decreasing manufacturing costs. The flat panel display includes a substrate, a first electrode layer formed on the substrate, ink with material for a light emission layer formed on an active area of the first electrode layer, a repellant area formed of organic material located around the active area, and a border area also formed of organic material located between the active area and the repellant area. A surface energy of the border area is higher than a surface energy of the repellant area.

Abstract: The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of ?-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

Abstract: The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like.

Abstract: An organic light-emitting diode (OLED) with an increased service life and a method of manufacturing the same are provided. The OLED is subjected to electromagnetic radiation with a spectrum that at least partially overlaps the absorption spectrum of an organic material layer of the OLED. As a result, the OLED has a longer service life, reduced decay in its initial brightness, and more saturated color than a conventional OLED.

Abstract: The invention on hand refers to diseases associated with abnormal protein structures, including Alzheimer's disease, Creutzfeldt-Jakob's disease, BSE and other prion-associated diseases. It is the task of the invention on hand to provide new active agents preventing the formation of amyloid plaques and to dissolve existing plaques, such agents being convenient for therapy, diagnosis and prophylaxis of diseases that are associated with abnormal protein structures. This task is performed in terms of the current invention by heterocyclic or aromatic agents with a rigid structure and a donor-acceptor-donor pattern (DAD), the latter being formed by donors and acceptors of hydrogen bridge linkages which comply with the ?-sheet structure of the peptide or protein and thus fit as binding partners. The heterocyclic or aromatic agents are available at least as dimers. They recognise peptides and proteins with a ?-sheet structure, form stable complexes with them and inhibit their aggregation to ?-amyloid plaques.